Danai-Maria Kotzampasi

Ms. Danai-Maria Kotzampasi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Athanasios A. PanagiotopoulosAthanasios A. Panagiotopoulos
Athanasios A. Panagiotopoulos
IKIoannis Karakasiliotis
Ioannis Karakasiliotis
DKDanai-Maria Kotzampasi
Danai-Maria Kotzampasi
MDMarios Dimitriou
Marios Dimitriou
GSGeorge Sourvinos
George Sourvinos
VDVangelis Daskalakis
Vangelis Daskalakis
3CL-Pro is the SARS-CoV-2 main protease (MPro). It acts as a homodimer to cleave the large polyprotein 1ab transcript into proteins that are necessary for viral growth and replication. 3CL-Pro has been one of the most studied SARS-CoV-2 proteins and a main target of therapeutics. A number of drug candidates have been reported, including natural products. Here, we employ elaborate computational methods to explore the dimerization of the 3CL-Pro protein, and we formulate a computational context to identify potential inhibitors of this process. We report that fortunellin (acacetin 7-O-neohesperidoside), a natural flavonoid O-glycoside, and its structural analogs are potent inhibitors of 3CL-Pro dimerization, inhibiting viral plaque formation in vitro. We thus propose a novel basis for the search of pharmaceuticals as well as dietary supplements in the fight against SARS-CoV-2 and COVID-19.